Physician profile
John K Bartnik
NPI 1740211275
$4,750.41
in general payments reported to CMS, 2019-2025
50 companies · $996 in 2025
The $996 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $495 · 2021: $194 · 2022: $111 · 2023: $980 · 2024: $715 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.41 |
| Education | $403.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $679.43 | 2019-2025 | |
| Janssen Biotech, INC. | $583.00 | 2019-2025 | Carvykti, Darzalex, Tecvayli |
| Genentech USA, INC. | $436.54 | 2019-2025 | Tecentriq, Venclexta, Itovebi |
| Exelixis INC. | $302.33 | 2023-2024 | Cabometyx |
| Pfizer INC. | $248.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $208.69 | 2019-2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $185.11 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $151.92 | 2019-2024 | Opdualag |
| Aveo Pharmaceuticals, INC. | $145.94 | 2023-2025 | Fotivda |
| Astellas Pharma US INC | $142.93 | 2023-2025 | Xospata |
| Eisai INC. | $129.44 | 2019-2024 | |
| Celgene Corporation | $112.07 | 2019-2023 | Reblozyl, Opdualag |
| Amgen INC. | $99.25 | 2019-2023 | |
| Gilead Sciences, INC. | $92.71 | 2019-2024 | Trodelvy |
| Lilly USA, LLC | $92.37 | 2019-2025 | Jaypirca, Verzenio |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bartnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.